Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
Abstract Background Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor that has been widely applied as a standard first-line treatment in advanced non-small cell lung cancer. However, the risk signals of osimertinib-related myotoxicity have not yet been full...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2025-08-01
|
| Serie: | BMC Cancer |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12885-025-14743-3 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|